ArticleCancer medicine2026
Clinical Characteristics and Prognostic Prediction of Secondary Solid Malignancies in Patients With Diffuse Large B-Cell Lymphoma and Follicular Lymphoma.
Article in Cancer medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSecondary primary solid malignancies (SPSMs) significantly impact long-term outcomes in lymphoma patients. However, subtype-specific differences remain unclear, such as diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL).
methodsThis study collected 1,377 DLBCL and 489 FL patients, identifying 50 DLBCL and 31 FL cases with SPSMs. Clinical characteristics, SPSM types, and survival were compared in these 81 patients. Demographic, clinical, treatment-related variables (including radiotherapy for primary lymphoma, recorded as yes/no), and survival outcomes were collected. Overall survival (OS) was analyzed using Kaplan-Meier estimates and Cox proportional hazards models. The cumulative incidence of SPSMs was evaluated with competing risk analysis (death as a competing event), and group comparisons were performed with Gray's test. Prognostic factors identified in univariable analysis (p < 0.05) were included in a multivariable Cox model. A nomogram was developed, with discriminative ability assessed by the area under the receiver operating characteristic curve (ROC). Statistical significance was set at p < 0.05.
resultsSPSMs were observed more frequently in FL (6.34%) than DLBCL (3.63%). Thyroid cancer predominated (22.2%, 18/81). DLBCL patients developed SPSMs earlier than FL patients (median 28.47 vs. 41.77 months, p = 0.031), though cumulative incidence accounting for competing risks did not differ significantly (Gray's test p = 0.34). DLBCL patients with SPSMs had inferior OS compared to FL patients (p = 0.04). Non-GCB DLBCL showed greater SPSM diversity and survival disadvantage. Multivariable analysis identified FL (vs. DLBCL) subtype (HR = 0.328, p = 0.018), bone marrow infiltration (HR = 2.815, p = 0.014), initial radiotherapy before SPSM diagnosis (HR = 3.475, p = 0.005), and shorter time to SPSM development (HR = 0.973 per month, p = 0.021) as independent prognostic factors for worse OS. The nomogram model showed acceptable discrimination, with an AUC of 0.761 in the time-dependent ROC analysis.
conclusionThis study provides novel insights into SPSM characteristics and prognostic differences in DLBCL and FL patients within a Chinese cohort. SPSMs in FL patients were observed more frequently, while DLBCL patients, particularly those with non-GCB subtypes, experience earlier SPSM onset and poorer survival. The validated nomogram, incorporating lymphoma-related factors, enables personalized risk stratification. However, the single-center design, small sample size (n = 81), and lack of SPSM-specific data limit generalizability, necessitating multi-center studies with comprehensive SPSM characterization for validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.